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ABSTRACT
Ultrasound is well known as a low-cost, radiation-free and effective imaging technique to guide percutaneous procedures.
The lower limbmuscles represent a good target to perform such procedures under ultrasound guidance, thus allowing for
clear and precise visualization of the needle during the whole procedure. The knowledge of guidelines and technical
aspects is mandatory to act in the most safe and accurate way on target tissues that can be as small as a few millimetres.
This review will focus above the local treatments of traumatic lower limb muscle injuries described in literature, focusing
on new and promising approaches, such as platelet-rich plasma treatment of muscle tears in athletes. For each procedure,
a brief how-to-do practical guide will be provided, emphasizing precautions and tricks based on day-by-day experience
that may help to improve the outcome of percutaneous ultrasound-guided procedures around the lower limb muscles.
INTRODUCTION
Over the past decade, with recent technological advance-
ments, interventional musculoskeletal (MSK) image-guided
procedures have been increasingly spread in clinical prac-
tice. Dynamic high-resolution ultrasonography has
emerged as the referential imaging modality to guide in-
ﬁltrative manoeuvres in many articular, tendon and muscle
pathologies. Ultrasound is a quick, portable and cost-
effective method that offers the possibility of a real-time
visualization of both the target structure and the needle
during the entire procedure, allowing the operator to reach
the precise injection site (high drug-deposition accuracy).
It allows for careful avoidance of crucial structures such as
neurovascular bundles, thus reducing the risk of
complications.1–6 Moreover, the lack of ionizing radiation
makes ultrasound-guided injection techniques safe and
repeatable. These various advantages have contributed to
expansion in the routine application of ultrasound guid-
ance in the ﬁeld of MSK interventional procedures; indeed,
ultrasound-guided percutaneous treatments have gradually
replaced the traditional blind manoeuvres in respect to
which they offer a better patient outcome in terms of pain
reduction during and after the injection or aspiration,
greater efﬁcacy and improvement of post-procedural ar-
ticular or muscular functionality.7–9
Currently, a large number of percutaneous minimally in-
vasive treatments can be performed under ultrasound
guidance: aspiration of joint ﬂuid collections, drug in-
jection in the joints, tendon sheaths, bursae and perineural
soft tissues, lavage of tendon calciﬁcations, tendon dry
needling, injection of regenerative agents in injured ten-
dons and muscles, aspiration of muscular haematomas and
biopsies of soft-tissue masses.
One of the main MSK clinical ﬁelds in which these
ultrasound-guided inﬁltrative procedures have created in-
terest is sports medicine. Sport physicians are familiar with
tendon and especially muscle injuries; muscular contusions
and strains represent the most common ﬁndings, accounting
for approximately 10–55% of all sport-related lesions.10,11 In
particular, the hamstrings, rectus femoris, gracilis and me-
dial head of the gastrocnemius are typically involved.12,13
Muscle injuries have an important impact especially on pro-
fessional athletes because they are the most frequent cause of
days lost from training and competition.14 Thus, the primary
aim of the medical staff of professional clubs is to promote
a full recovery with a rapid return to play of the injured athlete. In
this setting, besides the traditional conservative treatments (rest,
ice, compression and elevation protocols, non-steroidal anti-
inﬂammatory drugs, physical therapy and functional rehabilitation),
in recent years, with current biotechnological innovations, additional
therapeutic ultrasound-guided options have been developed.15,16 A
number of biological factors such as the platelet-rich plasma (PRP)
and stem cells can be directly injected under ultrasound guidance at
the site of the lesion to facilitate muscle regeneration and minimize
the formation of a dense scar tissue. The goal of these novel agents is
to improve the healing process of the injured muscle with a return to
pre-injury muscle functionality as soon as possible. Another useful
application of ultrasound-guided procedures is intermuscular or
intramuscular haematomas aspiration, which may be performed in
selected cases.
Our review focuses on the most widely accepted interventional
ultrasound-guided procedures employed to treat skeletal muscle
sport-related injuries; in particular, platelet concentrate injection
and evacuation of muscular haematomas, with few consid-
erations about new perspectives. We will also discuss some
useful practical aspect required to perform safe and accurate
interventional procedures.
Basic principles of ultrasound-guided
interventional procedures
The following considerations should be kept in mind prior to
any procedure.
Basic clinical information
A preliminary accurate collection about the patient’s medical
history is recommended. In particular, referring to traumatic
muscle injuries, it is important to ask the patient when the
trauma happened and elucidate the dynamics of the trauma.
Past medical history, family medical history and personal/social
medical history could be helpful to correctly evaluate the patient.
Further considerations should be assessed about possible history
of drug allergies, consumption of anticoagulant/antiplatelet
drugs or the presence of blood-thinning pathologies that could
cause severe bleeding after the procedure.
Contraindications, complications and
informed consent
Ultrasound-guided interventional MSK manoeuvres are minimally
invasive and associated with a low complication rate; however, the
operator must give details about the contraindications and po-
tential complications related to the planned procedure to the pa-
tient for obtaining verbal and written informed consent.
Patient positioning
The patient must be placed on the examination table in a com-
fortable position in order to avoid any potential movements
during the procedure.
Antisepsis
All ultrasound-guided interventional manoeuvres require an
aseptic setting in order to avoid any risk of contamination and
secondary infectious. Antisepsis includes operator sterility, probe
and skin antisepsis. Many published data show that these proce-
dures are secure in order to prevent secondary infections.1,17,18
Probe selection
The choice of the probe is based on the depth of the target structure.
During MSK interventional procedures, linear phased array probes
(5–12MHz up to 18MHz) are usually preferred because they allow
a high-resolution visualization of superﬁcial structures. Deep muscle
injuries, athletes with large muscular mass or obese patients may
require the use of a convex probe (3–5MHz).
Interventional equipment
Needle choice should be based mainly on the depth of the ana-
tomic structure to treat. Also the density concentration of the
drug to inject and the expected viscosity of the ﬂuid to aspirate
must also be considered. Spinal needles are used for deep loca-
tions, athletes with large muscular mass or obese patients. Fre-
quently, 18–20G needles are used for many interventional
procedures; dense blood collections may require larger (14–16G)
needles. Single-use syringes, drainage tubes and catheters are
preferred. The choice of syringe size strictly depends on the
amount of ﬂuid to inject or drain.
Ultrasound-guided interventional procedure
A preliminary ultrasound evaluation is recommended in order
to identify the most reliable procedure setting and to conﬁrm
the expected ﬁndings. The interventional manoeuvres can be
performed using two main approaches: coaxial and lateral. In
the lateral approach, the needle is placed and inserted parallel to
the ultrasound beam, on the short side of the probe; it has the
advantage of excellent visibility of the needle during the entire
procedure, allowing the operator to reach the precise site of
injection/aspiration. The coaxial approach is burdened by re-
duced needle visibility; it can be used when the space around the
target is greatly restricted.
Ultrasound-guided aspiration procedures
As mentioned previously, contusive and/or strain traumas ac-
count for the majority of sport-related injuries. Usually, they
are managed with a conservative approach and heal sponta-
neously after variable amounts of time with complete restoring
of the tissue.10,19 In some cases, the natural course of such
injuries do not completely take place and some complications
may occur. These complications can induce many clinical
manifestations which variably modify patient outcome and
management during rehabilitation period: chronic haemato-
mas and muscle atrophy may delay the healing process, a pre-
dominant scar tissue may increase the risk of injuries
recurrence and myositis ossiﬁcans may simulate a soft-tissue
tumour, in particular when clinical data are unclear.
Ultrasound-guided percutaneous procedures play an important
role in some of those cases.20,21
Haematomas
Muscle haematomas represent the direct consequence after
a muscular strain or contusion. They could be intramuscular
when conﬁned within a single muscle, among its ﬁbres, or
intermuscular when located between two or more muscles,
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along fascial planes.22 Intramuscular haematomas are less
common; they may decrease in dimension over time but are less
likely to resolve spontaneously than intermuscular haematomas.20,22
A chronic haematoma is frequently seen in the triceps surae
muscle in tennis leg setting, as a consequence of a tear in-
volving the aponeurosis between the soleus and gastrocnemius
muscles;23,24 another common location is the vastus inter-
medius muscle, which is particularly prone to developing
haematomas after contusive traumas owing to its location just
over the femur.25
At ultrasound evaluation, initially haematoma may demonstrate
variable appearance with muscle swelling and oedema, ranging
from anechoic or hypoechoic to hyperechoic. As the organiza-
tion progresses in the subsequent 2–3 days, the walls become
more evident and the amount of ﬂuid becomes progressively
hypoechoic or anechoic: this is the ideal time for ultrasound
examination to detect haematomas in case of low-grade mus-
cular strain.10,19 Following weeks after injury, the amount of
ﬂuid progressively decreases and its echogenicity increases;
meanwhile, its walls thicken towards the centre until the ﬂuid
closes. Many times, the ﬂuid component does not appear as
homogeneously hypo-anechoic but may present increased cen-
tral echogenicity and ﬂuid/debris levels.23 Usually chronic
muscular haematomas take many weeks to resolve but some-
times do not resolve spontaneously, resulting in signiﬁcant delay
in the return to sport practice and predisposing to possible
complications such as partial calciﬁcation, cyst formation,
myositis ossiﬁcans, neural compression and even expansion,
causing compartment syndrome.19–23,26 In those cases in which
chronic haematomas do not resolve in time, ultrasound-guided
percutaneous aspiration represents the ﬁrst-line approach in
order to drain the ﬂuid collected and promote the healing
process.6 However, consider the risk of infection during pro-
cedure, in particular in incompletely aspirated collections of
blood. Aspiration may be used if there is severe pain, in par-
ticular in case of signiﬁcant intermuscular haematomas, or to
promote early healing (i.e. for elite athletes). Further, ultrasound
is useful to identify features that could increase procedure dif-
ﬁculty (i.e. extensive loculation of the haematoma during
organization).20
By deﬁnition, aspiration refers to the use of a catheter or needle to
evacuate ﬂuid collection with immediate post-procedural removal
of the needle or catheter (without continuous drainage).27 The
procedure cannot be performed until most of the haematoma has
sufﬁciently liqueﬁed; so, the ideal time is between 1 and 2 weeks
after injury. This appearance can be assessed by repeated ultra-
sound scans of the ﬂuid collection, evaluating the internal echo-
texture and haematoma compressibility under pressure of the
transducer. Ultrasound-guided needle aspiration of the haema-
toma can easily be performed with a freehand technique, until
complete evacuation; a 10ml syringe and 18–20-G standard
needle are generally appropriate; pressing the tissues around the
collection in order to increase the amount of ﬂuid to be aspirated
may be a helpful manoeuvre (Figure 1).
A thigh elastic bandage must be performed after the procedure
in order to avoid the possibility of recurrence of the ﬂuid
collection and a period of rest of about 24–48 h is indicated.28
After 1 week of the procedure, it is useful to review the outcome
of the procedure with a ultrasound follow-up: if the haematoma
has recurred, it is possible to perform the aspiration again.
Usually haematoma aspirations do not need any subsequent
drug injection; anyway, a small amount of corticosteroid can be
injected at the same site at the end of the procedure,27–29 in
particular in case of recurrence of the haematoma and/or only
partial aspiration of the ﬂuid collection.
Cysts
Sometimes, after muscular traumas, intermuscular and/or in-
tramuscular cysts may be detected at follow-up. They represent
the residue of a local pre-existing haematoma, in most cases
signiﬁcant in terms of dimension. They can stand for months
and their most common location is the calf, but some cases are
reported also in the rectus femoris, semi-membranosus and
semi-tendinosus muscles. Usually cysts have an elongated shape
according to the three-dimensional disposition of the muscular
ﬁbres and the fascial planes in which they are located. At ul-
trasound examination, they appear as well-deﬁned anechoic
lesions with posterior acoustic enhancement.30 Although imag-
ing features of cysts are usually pathognomonic, it is very im-
portant to relate such ultrasound ﬁndings to the history of
traumatic injuries: always consider the differential diagnosis list
which includes the synovial cyst or articular ganglia and bursae;
as for chronic haematomas, in rare cases, some soft-tissue
tumours (i.e. myxoma, sarcoma) may present cystic appearance
and, in the absence of a history of trauma, it is mandatory to
investigate the nature of such lesion with further imaging mo-
dalities (i.e. MRI with contrast material), in particular if the
lesion presents wall thickening or internal complexity.31,32
Ultrasound-guided needle aspiration of the cyst can easily be
performed with a freehand technique and a 18–20-G needle
until complete evacuation.
Figure 1. Ultrasound-guided aspiration of a large gemellus
medialis (GM) haematoma (*) using a 20-G spinal needle (arrow).
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Morel-Lavalle´e
Morel-Lavalle´e lesion is a post-traumatic haemolymphatic col-
lection occurring after a shearing injury with disruption of
interfascial planes between the subcutaneous fat tissue and deep
fascia and muscle. Such lesions have different possible pre-
sentations ranging from seroma to chronic organizing and/or
expanding haematoma.33 Their most common location is the
thigh at the level of the greater trochanter but may also be
present around the knee;34 other possible locations are the calf
and trunk. When not treated in acute setting, Morel-Lavalle´e
lesion may develop an inﬂammatory reaction and, subsequently,
a ﬁbrous capsule, which contributes to the self-perpetuation and
eventual slow growth of such process. Various treatment options
are reported and include conservative approaches such as
compression banding, aspiration, surgical drainage, incision and
evacuation with or without sclerosing agents and radical sur-
gery.35 When the lesion is not associated with bone fractures
and/or infections and the skin is viable, percutaneous aspiration
under ultrasound guidance is possible; considering the signiﬁ-
cant dimensions of this kind of lesions, it is appropriate to use
a 16–18-G needle or cannula, coupled with a 10–20ml syringe
(Figure 2). It is reported that a high amount of ﬂuid and the
presence of a ﬁbrous capsule may increase the possibility of
recurrence of the lesion. Many case reports reported limited
success with percutaneous aspiration, often requiring repeated
aspirations, with time to healing ranging from 4 weeks to
10 months. Some authors35,36 proposed useful algorithms to
manage Morel-Lavalle´e lesions; in particular, the Mayo clinic
experience36 proposed operative intervention in the presence of
ﬂuid collection of .50ml.
PLATELET-RICH PLASMA INJECTION
By deﬁnition, the term PRP describes a preparation obtained
from peripheral blood with enrichment of the platelet
fraction.37,38 It has been used for decades to accelerate tissue
repair during surgery and to treat large or non-healing tears, and
since then it has progressively gained a role as an agent of tissue
regeneration.39,40 In 2007, the term and deﬁnition of PRP was
introduced in Pubmed as a medical subject heading to be used
for indexing scientiﬁc articles, suggesting its application in
a variety of clinical settings: focusing on sports medicine and
orthopaedics ﬁelds; it has been proposed for osteoarthritis,
tendinopathies, muscle and tendon injuries, ligamentous inju-
ries, peripheral neuropaties and plantar fascitiis.40,41
The rationale of using PRP resides in the physiological process
of healing after tissue damage. It is a complex regenerative
process, which comprises immune response [leukocyte in-
ﬁltration, cellular apoptosis, release of cytokines and growth
factors (GFs) and macrophage polarization], angiogenesis,
stem cell activation, nerve repair and mechanical stimuli. All
these biological responses are coordinated and regulated
through the secretion of multipleGFs and cytokines, released
by satellite cells, macrophages, platelets, endothelial cells and
myoﬁbroblasts.42–46 The entire process usually take place in at
least 1 month and leads damaged tissue through an in-
ﬂammatory phase, reparative phase and remodelling phase to
the complete reconstitution of the tissue. The healing process is
achieved through the regeneration of muscle ﬁbres and the
formation of a ﬁbrotic tissue; the balance between these two
mechanisms (acting simultaneously and competitively) repre-
sents a crucial point and is at the centre of many studies.
The rationale behind PRP use is to stimulate platelets to release
these factors and promote myogenesis, angiogenesis and inner-
vations, and modulate immune response and ﬁbrogenesis to
enable functional muscle healing in order to hasten muscular
ﬁbres repair and reduce pain during rehabilitation.43,47,48 In our
experience, PRP-treated injuries may present different patterns
of healing process (seroma, ﬁbrous scar and regenerative tissue)
depending on the severity of the injury, on the subjective in-
ﬂammatory response of the patient and on the rehabilitative
mobilization protocol (Figure 3a,b).
The mechanical stimuli sought and promoted during re-
habilitation are essential to the optimal outcome of the PRP
usage for injury recovery (myogenesis stimulation, correct
alignment of new ﬁbres and proper innervation promotion).
Preparations of PRP may be obtained from the transfusion
medicine service of the hospital or prepared using disposable
kits. Predetermined PRP concentrations and almost no risk of
contamination represent the advantages of using disposable kits,
with the higher cost to be taken into consideration.
Many different preparations of PRP are available which differ
among themselves in the platelet concentration, release rate of
GFs, white and red cell concentration, centrifugation and acti-
vation method.37,49–52
In 2009, Dohan et al53 proposed the present nomenclature and
classiﬁcation of platelet-rich preparations based on the cell
content and the ﬁbrin architecture: pure or leukocyte-poor PRP,
referred to as P-PRP, and leukocyte PRP, termed L-PRP, which
are injectable PRP preparations used in sport medicine as liquid
solutions or activated gel forms.54 Reported data indicate that
Figure 2. Drainage of a well-defined hypo-anechoic fluid
collection (Morel-Lavallee lesion) (*), superficial to the linear
echogenic deep fascia (M). S, subcutaneous fat; 18-G can-
nula, arrow.
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L-PRP contains 5-fold to 8-fold more platelets and more leu-
kocytes than peripheral blood, pure or leukocyte-poor PRP has
a lower increase in platelet count (1.5- and 2.5-fold above
baseline) and leukocytes are absent.41,55
In the following years, other authors reported lists of different
preparations commercially available: Mishra et al56 proposed
a classiﬁcation only for sports medicine applications and taking
into consideration platelet and leukocyte concentrations. An-
other system called PAW (platelets, activation, white cells) fo-
cuses on the platelet quantity, the activation modality of the
platelets and the presence of leukocytes.57
PRP could be prepared also with centrifugation at transfusional
centre. This preparation method gives the possibility to match
the needed PRP amount and concentration with the various
clinical settings; it has lower costs but the presence of a trans-
fusional centre is mandatory. The procedure starts by collecting
a whole venous blood sample (40–50ml) from a patient usually
from the cubital vein, and it is mixed with citrate to prevent
early clotting. Then, it is centrifuged by the transfusion centre
for about 15min (depending on the centrifugation method),
and a small sample is taken in order to determine the absence of
contamination. The centrifugation separates blood components
such as red cells (which are discarded) and gather and con-
centrate the platelets and, depending on the type of preparation,
the leukocytes. In the end, usually 4–10ml of PRP solution
is gained.
Another crucial point to be taken into consideration is PRP
activation, which is the mechanism through which the secretion
of granules is induced. One possibility is the simultaneous in-
jection of PRP and 1–2ml of calcium gluconate solution by
a two-way syringe in order to cleave ﬁbrinogen with subsequent
polymerization of ﬁbrin monomers (10–40 s after injection).
Alternatively, physiological activation can be obtained by
injecting the unactivated PRP into the site of ﬁbre injury: the
contact with collagen and other tissue factors will activate PRP.
Some studies determined that most of the GFs are released
within 10min of activation.58 However, unactivated PRP must
also be injected as soon as possible after centrifugation in order
to prevent geliﬁcation.
In our experience, exogenously activated PRP may be used in
particular in small, focal grade II intramuscular strain, where its
potential role in the promotion of the ﬁbrin clot may help to
both accelerate the cellular phase and favour the regenerative
process; in such cases, 2–6ml of PRP could be enough even if
the amount of injected solution must be related to the di-
mension of the injury. In case of larger lesions and/or in par-
ticular involving the epymisium and/or the fascial planes, up to
10ml of PRP may be injected seeking endogenous physiological
activation through its contact with collagen and other in-
ﬂammatory mediators into the site of the injury.
General workflow for ultrasound-guided platelet-
rich plasma injection
• Pre-interventional planning including an organized tray with
all needed materials and preliminary ultrasound evaluation of
the lesion.
• Proper patient positioning and sterility procedures as already
described.
• Venous blood sample collection and coagulation prevention.
• Centrifugation of the blood sample in order to obtain platelet-
rich concentrates/L-PRP solutions.
• Needle insertion into the site of injury under ultrasound
guidance (Figure 4a).
• Autologous L-PRP/commercially available L-PRP injection
through a two-way syringe: if pre-activation is desired,
calcium gluconate and L-PRP solution should be injected
simultaneously under ultrasound guidance.
• Needle extraction, plaster positioning and ice application for
few minutes.
The timing of injections is another debated point among
authors; the proposed protocols are variable in terms of number
of injections and interval between each ones: in this setting, one
to three injections performed weekly after muscular injury, in
relation to the site and entity of the muscular lesion, could be
optimal in clinical practice (Figure 4b,c).
The role of PRP in the treatment of MSK pathologies was in-
vestigated in many studies;42,58–67 in vitro evidence supports the
clinical applications and gives clear indications to the potential
mechanisms of PRP.16,49,68–70 Some clinical studies focused on
Figure 3. Muscle tear outcome patterns at ultrasound follow-up of patients 20 days after treatment with platelet-rich plasma.
(3a) Wide hyperechoic fibrotic tissue (*) affecting the lateral aspect of the rectur femoris (RF) muscle. (b) Deep pseudocystic lesion
affecting the semi-membranosus (SM) muscle. In this case, the treated tear (*) is healed with a residual seroma (arrows).
Review article: Ultrasound-guided procedures to treat sport-related muscle injuries BJR
5 of 9 birpublications.org/bjr Br J Radiol;89:20150484
tendinopathy and demonstrated the validity of such a thera-
peutic option.71–74 However, other studies on large series have
reported that PRP treatment of tendinopathy is no more effec-
tive than placebo.75–77
This consideration could be partially translated to also muscular
injuries: the effects of PRP formulations to favour muscle
healing were reported in many case series showing variable
results.78–80 In particular, two recent randomized controlled
trials reported divergent results.81,82 Published data indicate that,
to date, the clinical use of PRP preparations remain widely de-
bated in the literature, probably because of the large quantity of
different protocols and preparations to be used in relatively
variable clinical settings with different rehabilitative manage-
ment. These issues need to be addressed before PRP can be used
routinely, and further research is warranted.
New perspectives—stem cell injection
Although PRP itself represents an interesting challenge for the
next years, stem cell (SC) applications could also play a prom-
ising role in sports injuries. They are undifferentiated cells with
the intrinsic ability to differentiate into different cell types.37 The
rationale behind its use resides in the physiological healing
process; PRP releases mediators with the aim of modulating the
inﬂammatory response to injury and promoting cellular re-
generation. On the other hand SC can be directly injected to
speed up the regeneration process. Hence, the applications are
similar to those for PRP alone with the added beneﬁt of re-
generative cell enrichment.37,83 To date, considering ethical
concerns and non-reported cancerogenic potential, mesenchy-
mal stem cells (MSCs) represent the most promising SC type to
be used;37,84 they are multipotent cells which can be obtained by
different tissues, such as the adipose tissue, synovial tissue and
bone marrow,85 and could be used as cell therapy by cell sus-
pension injections alone or in combination with PRP prepara-
tions. Results from in vitro and animal studies indicate the
potential use of MSCs to improve tendon and muscle
regeneration,83,86–90 but, in our knowledge, only some pilot
clinical trials have been conducted,90–92 indicating the need of
further studies to reveal the actual effectiveness of MSC therapy.
CONCLUSION
In summary, percutaneous treatment of sport-related muscle
injuries has been demonstrated to be effective in treating
a number of pathologic conditions. The use of ultrasound
guidance further improves the effectiveness of such treatments,
especially when dealing with PRP and aspiration of large and
partially coagulated haematomas.
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